A review: Application of water in pharmaceuticals
If BPC-157 was purchased today, the patent would likely expire in 2033 before the phase 1-2-3 trials would be completed, at which point all the generic manufacturers would be able to push the product on the back of all the hard work a pharmaceutical company can do (Im not sure if FDA approval would push the expiration of the patent back, but even then it would not be so financial lucrative)
The split dosing maintains more consistent tissue concentrations given peptide half-lives
Individual variation in response timing is normal and expected
BPC-157, short for Body Protection Compound-157, is a synthetic peptide derived from a protein naturally found in human gastric juice
The flow of urine to the bladder, produced by the kidneys, is prevented due to improper ureter function